KBC Group
ALNY icon

KBC Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

KBC Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.79M Sell
20,524
-327,670
-94% -$112M 0.02% 412
2025
Q4 		$138M Buy
348,194
+74,842
+27% +$33.1M 0.32% 63
2025
Q3 		$125M Buy
273,352
+79,802
+41% +$32.5M 0.3% 69
2025
Q2 		$63.1M Buy
193,550
+174,238
+902% +$48.2M 0.17% 119
2025
Q1 		$5.21M Sell
19,312
-10,714
-36% -$2.75M 0.02% 451
2024
Q4 		$7.07M Buy
30,026
+5,460
+22% +$1.44M 0.02% 432
2024
Q3 		$6.76M Buy
24,566
+9,470
+63% +$2.47M 0.02% 426
2024
Q2 		$3.67M Hold
15,096
– – 0.01% 494
2024
Q1 		$2.26M Buy
15,096
+1,187
+9% +$198K 0.01% 574
2023
Q4 		$2.66M Sell
13,909
-1,601
-10% -$273K 0.01% 564
2023
Q3 		$2.75M Buy
15,510
+1,390
+10% +$265K 0.01% 537
2023
Q2 		$2.68M Sell
14,120
-13,886
-50% -$2.75M 0.01% 560
2023
Q1 		$5.61M Buy
28,006
+21,629
+339% +$4.55M 0.02% 458
2022
Q4 		$1.51M Sell
6,377
-1,449
-19% -$309K 0.01% 644
2022
Q3 		$1.57M Buy
7,826
+172
+2% +$32.8K 0.01% 590
2022
Q2 		$1.12M Buy
7,654
+215
+3% +$30.5K 0.01% 645
2022
Q1 		$1.22M Buy
7,439
+200
+3% +$30.5K ﹤0.01% 669
2021
Q4 		$1.23M Sell
7,239
-7,610
-51% -$1.41M ﹤0.01% 690
2021
Q3 		$2.8M Sell
14,849
-13,195
-47% -$2.48M 0.01% 588
2021
Q2 		$4.75M Buy
28,044
+8,906
+47% +$1.3M 0.01% 632
2021
Q1 		$2.7M Hold
19,138
– – 0.01% 706
2020
Q4 		$13.7M Hold
19,138
– – 0.01% 720
2020
Q3 		$2.79M Sell
19,138
-30,318
-61% -$4.31M 0.01% 653
2020
Q2 		$7.32M Buy
49,456
+36,387
+278% +$4.91M 0.02% 449
2020
Q1 		$1.42M Buy
13,069
+2,058
+19% +$238K 0.01% 624
2019
Q4 		$1.27M Buy
11,011
+345
+3% +$34.4K 0.01% 816
2019
Q3 		$857K Buy
10,666
+2,935
+38% +$232K 0.01% 921
2019
Q2 		$561K Hold
7,731
– – ﹤0.01% 1030
2019
Q1 		$722K Hold
7,731
– – 0.01% 969
2018
Q4 		$564K Hold
7,731
– – 0.01% 904
2018
Q3 		$677K Hold
7,731
– – 0.01% 1029
2018
Q2 		$761K Hold
7,731
– – 0.01% 891
2018
Q1 		$921K Buy
7,731
+65
+0.8% +$8.38K 0.01% 806
2017
Q4 		$974K Buy
7,666
+6,719
+710% +$844K 0.01% 815
2017
Q3 		$111K Hold
947
– – ﹤0.01% 1178
2017
Q2 		$76K Hold
947
– – ﹤0.01% 1199
2017
Q1 		$49K Hold
947
– – ﹤0.01% 1282
2016
Q4 		$35K Sell
947
-21,753
-96% -$911K ﹤0.01% 1284
2016
Q3 		$1.54M Buy
22,700
+18,231
+408% +$1.29M 0.02% 641
2016
Q2 		$248K Hold
4,469
– – ﹤0.01% 1050
2016
Q1 		$281K Hold
4,469
– – ﹤0.01% 972
2015
Q4 		$421K Sell
4,469
-1,100
-20% -$102K 0.01% 837
2015
Q3 		$448K Sell
5,569
-7,552
-58% -$839K 0.01% 800
2015
Q2 		$1.57M Buy
+13,121
New +$1.57M 0.02% 616

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's ALNY Position: Q1 2026 in Review

KBC Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 94% in Q1 2026, selling an estimated $112M and leaving 20,524 shares worth $6.79M. The position accounts for 0.02% of the portfolio, ranked #412.

KBC Group first reported a position in ALNY in Q2 2015 and has held it in 44 quarters since. The position peaked at $138M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • KBC Group held 20,524 shares of Alnylam Pharmaceuticals worth $6.79M as of Q1 2026.
  • KBC Group sold 327,670 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $112M.
  • Alnylam Pharmaceuticals made up 0.02% of KBC Group's portfolio in Q1 2026, its #412 holding.
  • KBC Group first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
  • KBC Group's Alnylam Pharmaceuticals position peaked at $138M in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.